Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Renata Pharmaceuticals (Ireland) Limited has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit, giving the prosecution record a focused structure.
RUNYAN, SILVANA C is the busiest examiner, with 1 pending matter. Counsel can target the response to that examiner’s analysis of the pharmaceutical claims and document the technical basis for any amendment.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RUNYAN, SILVANA C | 1 | 82.5% | +17.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18729541 | Sustained Release Pharmaceutical Composition of Upadacitinib | RUNYAN, SILVANA C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18729541 | Sustained Release Pharmaceutical Composition of Upadacitinib | RUNYAN, SILVANA C | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18729541 | Sustained Release Pharmaceutical Composition of Upadacitinib | RUNYAN, SILVANA C | 1616 | §103 | Non-Final OA | — | Pending | Jul 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRenata Pharmaceuticals (Ireland) Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Silvana C Runyan has the most, with 1 of Renata Pharmaceuticals (Ireland) Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
